Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

BACKGROUND: CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-resistant prostate-cancer. METHODS: 44 Patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kübler, Hubert, Scheel, Birgit, Gnad-Vogt, Ulrike, Miller, Kurt, Schultze-Seemann, Wolfgang, vom Dorp, Frank, Parmiani, Giorgio, Hampel, Christian, Wedel, Steffen, Trojan, Lutz, Jocham, Dieter, Maurer, Tobias, Rippin, Gerd, Fotin-Mleczek, Mariola, von der Mülbe, Florian, Probst, Jochen, Hoerr, Ingmar, Kallen, Karl-Josef, Lander, Thomas, Stenzl, Arnulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468959/
https://www.ncbi.nlm.nih.gov/pubmed/26082837
http://dx.doi.org/10.1186/s40425-015-0068-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468959/
https://www.ncbi.nlm.nih.gov/pubmed/26082837
http://dx.doi.org/10.1186/s40425-015-0068-y

Ejemplares similares